Search
-
ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV
Media
Fostemsavir addresses a critical need for those with little to no treatment options left who are at risk of further disease progression
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-marketing-authorisation-for-rukobia-fostemsavir-a-first-in-class-attachment-inhibitor-in-combination-with-other-antiretrovirals/
First published: 08 February 2021
-
ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available
Media
Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-chmp-opinion-for-rukobia-fostemsavir/
First published: 11 December 2020
-
GSK presents promising phase 2a data for chronic hepatitis B treatment
Media
Chronic hepatitis B is a major global health problem that occurs when the body’s immune system is unable to fight off the virus.
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-phase-2a-data-for-chronic-hepatitis-b-treatment/
First published: 28 August 2020
-
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia
Media
Full results from ENABLE 1 & 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-iii-results-for-eltrombopag-in-hepatitis-c-virus-related-thrombocytopenia/
First published: 07 November 2011
-
ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe
Media
ViiV Healthcare announced that the European Committee for Medicinal Products for Human Use issued a Positive Opinion for Juluca.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/
First published: 23 March 2018
-
Tony Wood appointed Chief Scientific Officer designate, GSK
Media
Tony Wood appointed Chief Scientific Officer designate, GSK
https://www.gsk.com/en-gb/media/press-releases/tony-wood-appointed-chief-scientific-officer-designate-gsk/
First published: 19 January 2022
-
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Media
Shionogi-ViiV announced results received from Phase III SINGLE study of dolutegravir in treatment-naive adults with HIV-1.
https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv/
First published: 11 July 2012
-
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment
Media
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/
First published: 16 August 2016
-
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
Media
32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment/
First published: 23 February 2016
-
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1
Media
ViiV Healthcare presents positive long-term data from phase III study
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-long-term-data-from-phase-iii-study-demonstrating-efficacy-and-safety-of-cabotegravir-and-rilpivirine/
First published: 09 March 2020